Hengrui Pharma announced it has entered into agreements with GSK to develop up to 12 medicines to complement GSK’s respiratory, immunology & inflammation, and oncology pipeline. This agreement significantly increases Hengrui’s value in global strategies while providing new growth opportunities to GSK beyond 2031.
Key Takeaways
- The collaboration allows for the development and research of 11 new programs.
- GSK will begin to advance Hrs-9821 as it aligns with the company’s development plans.
- The agreement has the chance to increase to a $12 billion value dependent on programs and milestone progress.
Tony Wood, chief scientific officer at GSK, mentioned the implications of the agreement, saying, "We're delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact." 1
Selected programs were assessed based on potential to be labeled as best- or first-in-class, with the agreement including an exclusive worldwide license for a potential best-in-class PDE3/4 inhibitor Hrs-9821.
HRS-9821 leads the way
Currently in clinical development for treatment of chronic obstructive pulmonary disease (COPD), Hrs-9821 acts as an add-on maintenance treatment irrespective of background therapy and was a driving force in the agreement. The inclusion of Hrs-9821 supports GSK’s goal of treating a broad spectrum of patients suffering from COPD, including those suffering from dyspnoea, and patients who are less likely to receive corticosteroids or biologics due to disease profiles.
Early clinical and preclinical studies show that Hrs-9821 exhibits potent PDE3 and PDE4 inhibition leading to increased bronchodilation and anti-inflammatory effects. Alongside early test results, Hrs-9821 yields the ability to formulate a dry-powder inhaler that aligns with GSK’s established inhaled portfolio.
Additional benefits
Another crucial part of GSK’s and Hengrui’s agreement is the collaborative effort to generate upwards of 11 additional programs alongside Hrs-9821. Each individual program will have its own financial structure with Hengrui leading development until the completion of phase 1 trials including patients outside of China. Meanwhile, GSK will hold the exclusive option to continue the development and commercialization of each program worldwide, with exclusions in China, Hong Kong, Macau, and Taiwan.